← All trials
NCT06027853
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2023
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Sep 7, 2023
- Last posted
- Sep 7, 2023
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang UniversityReponsible party - principal investigator
- Zhejiang UniversityOfficial
- Zhejiang UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.